CureVac COVID-19 vaccine
Vaccine candidate against COVID-19 / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about CureVac COVID-19 vaccine?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
The CureVac COVID-19 vaccine (abbreviated CVnCoV) was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI).[2] The vaccine showed inadequate results in its Phase III trials with only 47% efficacy.[3] In October 2021 CureVac abandoned further development and production plans for CVnCoV and refocused efforts on a cooperation with GlaxoSmithKline.[4]
Parts of this article (those related to status and trials) need to be updated. (December 2021) |
Quick Facts Vaccine description, Target ...
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | CVnCoV CV07050101 |
Routes of administration | Intramuscular |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
DrugBank | |
UNII |
Close